



Achieving tomorrow's outcomes through education today.™

D.R.I.V.E.
LYMPHOMA AND MYELOMA
INVESTIGATORS SUMMIT

SUPPORT OPPORTUNITIES

WEDNESDAY, JULY 17, 2024

HYATT REGENCY MAUI RESORT AND SPA

D.R.I.V.E. LYMPHOMA AND MYELOMA INVESTIGATORS SUMMIT – MAUI, HAWAII

Disparities in clinical outcomes, research participation and enrollment continue to exist in the treatment of lymphoma and myeloma amongst ethnically diverse groups. Strategies to address are being developed by many groups including the international/national oncology and hematology medical societies. Additionally, disparate research enrollment has increasingly become recognized by government and as a result in 2022, the US congress passed the FDORA act, to help address these disparities, with a requirement for manufactures needing FDA approval of medicines and devices to submit diversity plans for pivotal trials. However, FDORA currently lacks legislated responses to the non-implementation of these diversity plans.

D.R.I.V.E. is a five-step strategy developed to help address cancer research enrollment disparities and has been published by Indy Hematology Education, Inc. (IHE), a 501(c), non-profit organization, based in Indianapolis. However, IHE recognizes that the widespread adoption of this and other principles requires a collective approach amongst clinical investigators, leading thought leaders and major medical societies. The Pan-Pacific Lymphoma conference, offers a unique opportunity for attending lymphoma and multiple myeloma thought leaders, the leadership of the major hematology and oncology medical societies to discuss and adopt a collective, practical approach to addressing and improving research participation of all people, and an opportunity to generate widely applicable data, and improved data applicability of lymphoma clinical research to patients under our care with data generalizability and transportability and possibly create a template for other disease states.

For more information visit [Practical strategies for creating diversity, equity, inclusion, and access in cancer clinical research: DRIVE. Blood Adv. 2023;7\(8\):1507-1512.](#)

D.R.I.V.E.

- D:** All clinical trials must include a Diversity Officer who is tasked just like a DSMB in safety to ensure a diversity plan is established, maintained, and modified during the course of each study to meet its accrual goals of inclusion and diversity.
- R:** Create a Ranking System for measuring the relative diversity of enrolled subjects in a clinical trial that are published with each trial.
- I:** Create an Individual/Personal diversity plan to ensure minority patients are enrolled or participating in clinical research.
- V:** Verify and ensure that podium presentations at major conferences are preferentially given to clinical trials meeting diversity goals.
- E:** Elevate, train, and recruit minority investigators to participate in all clinical trials.

AGENDA

AGENDA

CO-CHAIRS: **Ruemu E. Birhiray, MD, Matt Lunning, DO, FACP**

12:30pm – 1:00pm LUNCHEON

1:00 pm – 1:05 pm INTRODUCTION: Why Are We Here and What Can We All Do Together to Address Clinical Research Disparities in Lymphoma Research – **Ruemu E. Birhiray, MD**

1:05 pm – 1:20 pm PRESENTATION OF “CONSENSUS STRATEGY FOR IMPROVING ENROLLMENT IN LYMPHOMA and MYELOMA CLINICAL TRIALS” – **Matt Lunning, DO, FACP, Andrew Hantel, MD**

1:20 pm – 1:40 pm CONSENSUS STRATEGY: ASCO: What Can We Do Tomorrow? – **Sybil Green, JD, PharmD, ASCO Vice President for Diversity and Equity**

1:40 pm – 1:50 pm CONSENSUS STRATEGY: ASH: What Can We Do Tomorrow? **ASH President** or **Nathalie van Havre, MD, MS, FRACP**

- 1:50 pm – 2:00 pm CONSENSUS STRATEGY: FDA: What Can We Do Tomorrow? – **Nicole Gormley, MD**
- 2:00 pm – 2:10 pm CONSENSUS STRATEGY: MEDICAL JOURNAL EDITOR-IN-CHIEF: What Can We Do Tomorrow? - Editor-in-Chief, Blood Journal - **Nancy Berliner, MD, Brigham and Women's Hospital, Boston, MA**
- OR
- 2:00 pm -2:10 pm CONSENSUS STRATEGY: Recommendations for Lymphoma and Myeloma Clinical Research Investigators – **Christopher Flowers, MD**
- 2:10 pm – 2:25 pm OUR NEXT STEPS TOMMOROW – ADOPTING AND IMPLEMENTING THE CONSENSUS STRATEGY – **Karen Winkfield, MD, PhD**
- 2:25 pm – 2:50 pm DISCUSSIONS AND ADOPTING THE CONSENSUS STRATERGY: ADVISORS FACILATATORS: **Matt Lunning, DO, FACP, Andrew Hantel, MD, Karen Winkfield, MD, PhD, Christopher Flowers, MD, Ruemu Birhiray, MD**
- 2:50 pm – 2:55 pm CLOSING – **Ruemu E. Birhiray, MD** and **Matt Lunning, DO, FACP**

Note: The Agenda is subject to change

SUPPORT OPPORTUNITIES

PLATINUM LEVEL

Cost: \$15,000

- Verbal recognition of your support during the meeting
- On-screen recognition
- Logo on DRIVE web page and Handout
- Signage with logo and sponsorship of the DRIVE Luncheon
 - Distribute your branded items to attendees

GOLD LEVEL

Cost: \$12,000

- Verbal recognition of your support during the meeting
- On-screen recognition
- Logo on DRIVE web page and Handout
 - Distribute your branded items to attendees
- Signage with logo and sponsorship of the Beverage Bar

SILVER LEVEL

Cost: \$9,000

- Verbal recognition of your support during the meeting
- On-screen recognition
- Logo on DRIVE web page and Handout
 - Distribute your branded items to attendees
- Signage with logo and sponsorship of four Consensus Strategy Sessions

BRONZE LEVEL

Cost: \$6,000

- Verbal recognition of your support during the meeting
- On-screen recognition
- Logo on DRIVE web page and Handout

SUPPORT AGREEMENT

The organization below has elected to enter this contract with Indy Hematology Education, Inc. for the sponsorship option indicated below.



D.R.I.V.E. Lymphoma and Myeloma Investigators Summit – MAUI


Wednesday, July 17, 2024

CONTACT NAME	
TITLE	
COMPANY	
ADDRESS	
CITY	STATE ZIP CODE
PHONE	EXT
MOBILE PHONE	
EMAIL	
WEBSITE	

DRIVE SUPPORTER OPPORTUNITIES

<input type="checkbox"/>	Silver	\$9,000
<input type="checkbox"/>	Bronze	\$6,000

Questions: Call 317-841-7171 or email
Indyhr@conventionmanagers.com



DRIVE PAYMENT

Option Selected _____

\$ _____

Instructions to authorize agreement:

1. Make check payable to:
Indy Hematology Education, Inc.
(non-profit 501(c) Tax ID# 27-1725842)
2. Return completed signed form and payment to:
Indy Hematology Review
135 S. Mitthoeffer Rd.
Indianapolis, IN 46229

Signature – Agreeing to support the DRIVE Lymphoma Summit